Chairman of hard-right Reform UK party quits
Zia Yusuf's announcement came after he criticised the party's newest MP for asking Prime Minister Keir Starmer whether he would ban the wearing of burqas in the UK.
The resignation hints at unrest in arch-Eurosceptic Nigel Farage's party, which has already lost one MP since it secured a breakthrough result at last July's general election.
"Eleven months ago I became chairman of Reform. I've worked full time as a volunteer to take the party from 14 to 30 percent (voter support), quadrupled its membership and delivered historic electoral results," Yusuf wrote on X.
"I no longer believe working to get a Reform government elected is a good use of my time, and hereby resign the office," he added.
Earlier, the 38-year-old had slammed Sarah Pochin, who was elected in a by-election last month, for her question to Starmer on Wednesday.
"I do think it's dumb for a party to ask the PM if they would do something the party itself wouldn't do," Yusuf wrote on X.
He became chairman in July last year, shortly after Reform won 14 percent of the vote and five seats in parliament -- an unprecedented haul for a hard-right group in a British general election.
Yusuf was tasked with professionalising the group's grassroots operations and training up candidates ahead of what Farage has said will be a major challenge to Starmer's Labour party at the next general election, likely in 2029.
Anti-immigrant Reform has consistently led national opinion polls for several weeks now and won hundreds of councillors at local polls on May 1.
Farage said he was "genuinely sorry" that Yusuf had decided to stand down, but some analysts saw it as another example of the charismatic Brexit cheerleader falling out with a senior figure in his party.
"It's like deja vu all over again," political scientist Tim Bale wrote on X, citing Farage's previous leadership of UKIP and the Brexit Party.
"No-one but no-one gets to be bigger than big Nige," added the Queen Mary University of London politics professor.
Last month, former Reform lawmaker Rupert Lowe called Farage a "viper" after his dramatic suspension from the party over claims he had threatened Yusuf.
Prosecutors did not charge Lowe, citing "insufficient evidence".
pdh/jhb
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Canada's TD Bank names John MacIntyre board chair
(Reuters) -Canadian lender TD Bank said on Monday that John MacIntyre, currently serving as an independent director, will take over as chair of the board effective September 1. MacIntyre will succeed Alan MacGibbon, who will retire after more than a year in the role. "His (MacIntyre's) deep financial expertise and governance experience will support the Board as it continues to prioritize strong oversight and long-term value creation," the company said. The bank is undergoing a U.S. government-ordered anti-money laundering remediation program following a historic $3 billion penalty by regulators for lapses in its risk systems. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
16 minutes ago
- Business Wire
Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines, and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; 'Ono'), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of vimseltinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability. The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission (EC), which has the authority to approve medicines in the European Union (EU), issues a decision on Deciphera's marketing authorization application (MAA) for vimseltinib. This decision is expected in the second quarter of the fiscal year ending March 31, 2026. 'CHMP's positive opinion is an important milestone for the TGCT community in the European Union (EU), where there are currently no approved treatments for TGCT, and for vimseltinib, which is now one step closer to potential EU regulatory approval,' said Ryota Udagawa, President and Chief Executive Officer of Deciphera. 'We look forward to building upon vimseltinib's positive CHMP opinion as we work to bring this medicine to TGCT patients around the world in need of new treatment options.' The positive CHMP opinion is supported by compelling efficacy and safety results from the pivotal Phase 3 MOTION study of vimseltinib in patients with TGCT not amenable to surgery with no prior anti-CSF1/CSF1R therapy (prior therapy with imatinib or nilotinib allowed), compared to placebo, as well as the Phase 1/2 study of vimseltinib. In MOTION, vimseltinib demonstrated a statistically significant and clinically meaningful objective response rate (ORR) at Week 25 in the intent-to-treat (ITT) population, as assessed by blinded independent radiologic review (BIRR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), versus placebo (40% in vimseltinib arm vs 0% in placebo arm, p <0.0001). The primary endpoint was supported by statistically significant and clinically meaningful improvements in active range of motion, patient-reported physical functioning, and patient-reported pain observed in the vimseltinib arm compared to the placebo arm at week 25. The safety profile of vimseltinib is manageable and consistent with results previously disclosed in the Phase 1/2 clinical trial. About vimseltinib Vimseltinib is an oral switch-control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R. Vimseltinib has been developed using Deciphera's proprietary switch-control kinase inhibitor platform. ROMVIMZA™ (vimseltinib) is a kinase inhibitor approved in the United States for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. About Tenosynovial Giant Cell Tumor (TGCT) TGCT is caused by a translocation in colony-stimulating factor 1 (CSF1) gene resulting in overexpression of CSF1 and recruitment of colony-stimulating factor 1 receptor (CSF1R)-positive inflammatory cells into the lesion. TGCT is a rare, non-malignant tumor that develops inside or near joints. TGCT is caused by dysregulation of the CSF1 gene leading to overproduction of CSF1. TGCT is also known as giant cell tumor of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS), a diffuse-type of TGCT. TGCT is a locally aggressive neoplasm that can grow and cause damage to surrounding tissues and structures inducing pain, swelling, and limitation of movement of the joint. Surgery is the main treatment option; however, these tumors tend to recur, particularly in diffuse-type TGCT. If untreated or if the tumor continually recurs, damage and degeneration may occur in the affected joint and surrounding tissues, which may cause significant disability. For a subset of patients, surgical resection will potentially cause worsening functional limitation or severe morbidity, systemic treatment options are limited and a new therapeutic option for TGCT is needed. About Deciphera Pharmaceuticals, LLC Deciphera, a member of Ono Pharmaceutical Co., Ltd., is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Deciphera is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from Deciphera's platform in clinical studies, QINLOCK ® (ripretinib) is Deciphera's switch-control kinase inhibitor approved in many countries including the European Union and the United States for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ROMVIMZA™ (vimseltinib) is a kinase inhibitor approved in the United States for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. For more information, visit and follow us on LinkedIn and X (@Deciphera). About Ono Pharmaceutical Co., Ltd. Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of 'Dedicated to the Fight against Disease and Pain,' Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at Cautionary Note Regarding Forward-Looking Statements In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice.
Chicago Tribune
16 minutes ago
- Chicago Tribune
As President Donald Trump shows off his golf courses for Britain's leader, crisis in Gaza looms
EDINBURGH, Scotland — President Donald Trump once suggested his golf course in Scotland 'furthers' the U.S.-U.K. relationship. Now he's getting the chance to prove it. British Prime Minister Keir Starmer is meeting Monday with Trump at a golf property owned by the president's family near Turnberry in southwestern Scotland — then later traveling to Abderdeen, on the country's northeast coast, where there's another Trump golf course and a third is opening soon. During his first term in 2019, Trump posted of his Turnberry property, 'Very proud of perhaps the greatest golf course anywhere in the world. Also, furthers U.K. relationship!' Starmer is not a golfer, but toggling between Trump's Scottish courses shows the outsized influence the president puts on properties bearing his name — and on golf's ability to shape geopolitics. However, even as Trump may want to focus on showing off his golf properties, Starmer will try to center the conversation on more urgent global matters. He plans to urge Trump to press Israel to allow more aid into Gaza and attempt to end what Downing St. called 'the unspeakable suffering and starvation' in the territory, while pushing for a ceasefire in Israel's war with Hamas. Britain, along with France and Germany, has criticized Israel for 'withholding essential humanitarian assistance' as hunger spread in Gaza. Over the weekend, Starmer said Britain will take part in efforts led by Jordan to airdrop aid after Israel temporarily eased restrictions. But British Business Secretary Jonathan Reynolds acknowledged Monday that only the U.S. has 'the leverage' to make a real difference in the conflict. Still, asked about the crisis in Gaza on Sunday night, Trump was largely dismissive — focused more on how he's not personally gotten credit for previous attempts to provide food aid. 'It's terrible. You really at least want to have somebody say, 'Thank you,'' Trump said. The president added, 'It makes you feel a little bad when you do that' without what he considered proper acknowledgement. Starmer is under pressure from his Labour Party lawmakers to follow France in recognizing a Palestinian state, a move both Israel and the U.S. have condemned. The British leader says the U.K. supports statehood for the Palestinians but that it must be 'part of a wider plan' for a two-state solution to the Israel-Palestinian conflict. Israeli strikes kill at least 36 people in Gaza, officials say, as some aid restrictions are easedAlso on Monday's agenda, according to Starmer's office, are efforts to promote a possible peace deal to end fighting in Russia's war with Ukraine — particularly efforts at forcing Russian President Vladimir Putin to the negotiating table in the next 50 days. Trump in the past sharply criticized Ukrainian President Volodymyr Zelenskyy for also failing to express enough public gratitude toward U.S. support for his country, taking a similar tack he's now adopting when it comes to aid for Gaza. The president, though, has shifted away from that tone and more sharply criticized Putin and Russia in recent weeks. On Tuesday, Trump will be at the site of his new course near Aberdeen for an official ribbon-cutting. It opens to the public on Aug. 13 and tee times are already for sale — with the course betting that a presidential visit can help boost sales. What to expect, and what not to, at the UN meeting on an Israel-Palestinian two-state solutionProtesters have planned a demonstration in Balmedie, near Trump's existing Aberdeen golf course, after demonstrators took to the streets across Scotland on Saturday to decry the president's visit while he was golfing. Starmer and Trump are likely to find more common ground on trade issues. While China initially responded to Trump's tariff threats by retaliating with high import taxes of its own on U.S. goods, it has since begun negotiating to ease trade tensions. Starmer and his country have taken a far softer approach. He's gone out of his way to work with Trump, flattering the president repeatedly during a February visit to the White House, and teaming up to announce a joint trade framework on tariffs for some key products in May. Starmer and Trump then signed a trade agreement during the G7 summit in Canada that freed the U.K.'s aerospace sector from U.S. tariffs and used quotas to reduce them on auto-related industries from 25% to 10% while increasing the amount of U.S. beef it pledged to import. Discussions with Starmer follow a Trump meeting Sunday with European Commission chief Ursula von der Leyen at his Turnberry course. They announced a trade framework that will put 15% tariffs on most goods from both countries, though many major details remain pending. The president has for months railed against yawning U.S. trade deficits around the globe and sees tariffs as a way to try and close them in a hurry. But the U.S. ran an $11.4 billion trade surplus with Britain last year, meaning it exported more to the U.K. than it imported. Census Bureau figures this year indicate that the surplus could grow. There are still lingering U.S.-Britain trade issues that need fine-tuning. The deal framework from May said British steel would enter the U.S. duty-free, but it continues to face a 25% levy. U.K. Business Secretary Jonathan Reynolds said Monday that 'negotiations have been going on on a daily basis' and 'there's a few issues to push a little bit further today,' though he downplayed expectations of a resolution. The leader of Scotland, meanwhile, said he will urge Trump to lift the current 10% tariff on Scotch whisky. First Minister John Swinney said the spirit's 'uniqueness' justified an exemption. Even as some trade details linger and both leaders grapple with increasingly difficult choices in Gaza and Ukraine, however, Starmer's staying on Trump's good side appears to be working — at least so far. 'The U.K. is very well-protected. You know why? Because I like them — that's their ultimate protection,' Trump said during the G7.
